• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Advisory Committees

  • Print
  • Share
  • E-mail

Waivers for Conflicts of Interest for the May 6, 2010 Meeting of the Peripheral and Central Nervous System Drugs Advisory Committee

The Food and Drug Administration Amendments Act of 2007 (FDAAA), enacted on September 27, 2007, added a new provision regarding financial conflicts of interest, § 712 of the Federal Food, Drug, and Cosmetic Act (FD&C Act), effective October 1, 2007. Accordingly, for advisory committee meetings after October 1, 2007, FDA is granting waivers under 18 U.S.C. § 208 and § 712 of the FD&C Act, where applicable, when the relevant waiver standards in these statutes are met.

Waivers under 21 U.S.C. § 355(n)(4) were issued before October 1, 2007.  This provision was repealed, effective October 1, 2007, by the FDA.

Peripheral and Central Nervous System Drugs Advisory Committee Meeting

May 6, 2010

Eli Mizrahi, M.D.

Eli Mizrahi, M.D. 18 U.S.C. 208 waiver (PDF - 44KB)

Eli Mizrahi, M.D. Disclosure Document (PDF - 25KB)